Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
MRK Merck & Co. Inc. daily Stock Chart
Merck & Co. Inc.
IndexDJIA S&P500 P/E14.56 EPS (ttm)3.42 Insider Own0.04% Shs Outstand2.82B Perf Week2.36%
Market Cap140.27B Forward P/E13.17 EPS next Y3.78 Insider Trans-25.69% Shs Float2.82B Perf Month-2.64%
Income9.85B PEG2.10 EPS next Q0.92 Inst Own75.20% Short Float1.42% Perf Quarter-12.42%
Sales40.25B P/S3.49 EPS this Y176.90% Inst Trans0.02% Short Ratio3.35 Perf Half Y-11.44%
Book/sh16.44 P/B3.03 EPS next Y7.84% ROA9.60% Target Price62.94 Perf Year-13.72%
Cash/sh4.04 P/C12.34 EPS next 5Y6.92% ROE21.00% 52W Range45.30 - 62.10 Perf YTD-10.16%
Dividend1.80 P/FCF85.22 EPS past 5Y-6.30% ROI0.50% 52W High-19.80% Beta0.59
Dividend %3.61% Quick Ratio1.30 Sales past 5Y9.00% Gross Margin63.00% 52W Low9.93% ATR1.35
Employees70000 Current Ratio1.60 Sales Q/Q-10.50% Oper. Margin39.60% RSI (14)40.89 Volatility2.54% 2.40%
OptionableYes Debt/Eq0.57 EPS Q/Q-64.70% Profit Margin24.50% Rel Volume1.38 Prev Close51.23
ShortableYes LT Debt/Eq0.52 EarningsOct 27 BMO Payout51.40% Avg Volume11.96M Price49.80
Recom2.40 SMA20-2.74% SMA50-8.16% SMA200-12.54% Volume16,477,742 Change-2.79%
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Oct-06-15 05:40PM  Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published
05:07PM  Advaxis Cancer Immunotherapy on Hold Due to Patient Death at TheStreet
01:17PM  Would an Ebola Vaccine Move Regeneron Pharmaceuticals' Bottom Line? at Motley Fool
01:11PM  Health care stocks take a broad beating as sector turns negative on the year at MarketWatch
12:03PM  Has Valeant Fallen Too Far? at
12:11AM  Nobel in Medicine Awarded to Three for Advances Against Tropical Diseases at The Wall Street Journal
Oct-05-15 07:01PM  Results from MSDs Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet Business Wire
07:01PM  Results from Mercks Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet Business Wire
05:15PM  Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment Business Wire
01:32PM  Mega-caps that could be poised for big moves higher
12:48PM  How Common Is It for Companies to Raise Drug Prices?
11:40AM  Merck's (MRK) Keytruda Gains FDA Nod for Label Expansion
11:03AM  Why The 2015 Nobel Prize In Medicine Was The Boyhood Inspiration For A Chemist From Africa at Forbes
06:01AM  Ten-Year Bond Yields Drop Below Two Percent
Oct-03-15 09:15AM  5 Big FDA Decisions Expected in October at 24/7 Wall St.
Oct-02-15 10:27PM  FDA Approves Mercks Keytruda for Most Common Form of Lung Cancer at The Wall Street Journal
04:56PM  FDA Approves Merck's Keytruda for Lung Cancer at The Wall Street Journal
04:40PM  Merck KGaA's Pipeline on Track, Updates Key R&D Projects
03:32PM  U.S. FDA expands approval of Merck's Keytruda to lung cancer Reuters
02:49PM  FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy Business Wire
02:04PM  Merck Wins Approval to Expand Keytruda to Some With Lung Cancer at Bloomberg
02:01PM  FDA approves Merck's Keytruda for use in lung cancer Reuters
12:42PM  Alexion, Vertex Steal Mo Stanley's Eyes From Gilead at Investor's Business Daily
Oct-01-15 04:38PM  Bristol-Myers' gets early approval of combo cancer treatment
02:31PM  Gilead Sciences: 'Continued Dominance' at
09:15AM  BioMarin Buys Kuvan Drug Rights From Merck at TheStreet
08:00AM  Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer Business Wire
07:10AM  BioMarin to Acquire Global Rights to the Drug Kuvan at The Wall Street Journal
07:00AM  NewLink Genetics Awarded $18 Million Contract Option from BARDA GlobeNewswire
04:03AM  Germany's Merck sells rights to Kuvan back to BioMarin Pharma
Sep-30-15 05:06PM  How Did Sanofi Pasteur Perform in 2Q15?
12:54PM  Gilead: A Growth Story Trapped in a Value Multiple at
12:34PM  3 Big Drugs Likely To Hit The Market Soon at Investor's Business Daily
08:18AM  3 Reasons Pfizer Is the Strongest Big Pharma Play Now at TheStreet
Sep-29-15 05:16PM  Sigma-Aldrich Issues Update on Buyout by Merck KGaA
10:30AM  International Coalition Urges Final Push to Eliminate River Blindness from the Americas Business Wire
Sep-28-15 03:09PM  Sanofi settles lawsuit enabling rival to Lantus insulin
02:22PM  Roth Capital Upgrades ANI Pharmaceuticals To Buy On Valuation
01:37PM  A red start to the week
08:42AM  Clinton Proposals Could Spell Trouble for These 3 Drugmakers at Motley Fool
08:17AM  Merck's once-weekly diabetes drug approved in Japan Reuters
08:00AM  Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And KEYTRUDA® PR Newswire
07:30AM  MARIZEV® (Omarigliptin), Mercks Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan Business Wire
Sep-27-15 07:00AM  New Data from KEYNOTE-028, Mercks Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress Business Wire
01:00AM  Roche says new drug shows benefits in lung, bladder cancer tests Reuters
01:00AM  New Data from KEYNOTE-028, MSDs Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress Business Wire
Sep-26-15 01:00AM  New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma Business Wire
Sep-25-15 09:00PM  Bear With Us; Unloved Oil; Just Raise Rates Already: Jim Cramer's Best Blogs at TheStreet
06:02PM  Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer at TheStreet
06:00PM  Bristol's Opdivo boosts kidney cancer survival beyond two years Reuters
03:22PM  Dow 30 Stock Roundup: Boeing Receives Orders Worth $38B From China Cos, Caterpillar to Cut 5K Jobs
10:06AM  Akorns Revenue
08:40AM  Short Sellers Boost Positions in Major Pharma at 24/7 Wall St.
08:00AM  Merck to Hold Third-Quarter 2015 Sales and Earnings Conference Call on October 27 Business Wire
07:00AM  Merck's New Drugs Offset Patent Losses at Morningstar
Sep-24-15 05:51PM  Could Spark cure blindness?
12:40PM  Here's How Merck Plans to Protect Billions of Dollars in Sales at Motley Fool
09:45AM  Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter at 24/7 Wall St.
09:05AM  Stock Futures Down, Volatile; Accenture, Caterpillar Slide at Investor's Business Daily
Sep-23-15 12:37PM  How Mylan Turned EpiPen Into a Must-Have
10:10AM  Stock Market News for September 23, 2015
03:14AM  Bristol-Myers Squibbs Oncology Segment in 2Q15
Sep-22-15 05:30PM  Recall stocks: Buying opportunities?
04:55PM  Inovio Gets Grant for Ebola Drugs, Regeneron Inks Deal
04:51PM  Pfizer says it could be leader in cancer with many new drugs
10:10AM  Company News for September 22, 2015
07:36AM  Eli Lilly Officially Puts Merck on Notice at Motley Fool
07:04AM  Whats the Outlook for Eli Lilly?
Sep-21-15 07:01PM  Biotech stocks fall on Clinton vow to fight 'price gouging'
04:57PM  Stocks end higher, but health-care selloff caps gains at MarketWatch
04:50PM  Merck Reports Encouraging Phase III Data on Bezlotoxumab
04:36PM  What Drove Sanofis Growth in 2Q15?
02:16PM  Rally Flames Out as Health Care Sells Off at TheStreet
01:31PM  Stocks Turn Mixed as Rally Flames Out at TheStreet
01:21PM  Mallinckrodt, Merck, Biogen: What's Moving Markets
12:10PM  Gilead HCV Combo Hits In Trials, Could Broaden Market at Investor's Business Daily
11:20AM  Merck (MRK) Stock Price Target Reduced at BMO Capital Markets at TheStreet
10:43AM  All major averages jump 1% as stocks attempt bounce at CNBC
08:00AM  Data in Nine Difficult-to-Treat Cancers from Mercks KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ... Business Wire
06:01AM  The Cost of Sending the Wrong Message
Sep-20-15 12:30PM  Pivotal Phase 3 Studies of Bezlotoxumab, Mercks Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint Business Wire
12:30PM  Merck antibody reduces risk of C. difficile recurrence - study
Sep-18-15 03:00PM  Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015 Business Wire
11:00AM  Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley
10:32AM  Roche shows its intent with Switzerland's tallest skyscraper Reuters
08:02AM  Will The Next Hepatitis C Drugs Hit It Big? at Investor's Business Daily
Sep-17-15 04:29PM  Study: Type 2 diabetes pill Jardiance cuts risk of death
03:30PM  ENUM: An Biotech Company Focused on Identifying Antibodies Using Human Approach
02:08PM  Lilly Diabetes Drug Jardiance Cuts Death Rate By 32% at Investor's Business Daily
01:41PM  How Sweet It Is: Lilly Surges Above $90 on Diabetes Drug Data at
01:35PM  The Dow rose on the day the Fed first hiked rates in 2004, then fell over the next 3 months at MarketWatch
11:46AM  In Surprising Result, A Diabetes Drug Prevents Deaths. But How? at Forbes
09:27AM  These 5 Dow Components Have Upside Price Gaps To Fill After The FOMC Statement at Forbes
08:30AM  Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes Business Wire
07:57AM  Amgen's Acquisition Of Dezima And CETP Drug Like Pfizer's '03 Buy Of Esperion. Will History Repeat? at Forbes
Sep-16-15 02:41PM  Merck: Long-acting diabetes pill works same as its Januvia
01:51PM  Amgen buys 1 company, partners with 2nd to create new drugs
01:30PM  The Safest Stock To Own In Any Market
11:18AM  Amgen Buying Into Risky New Cholesterol Drug Class at Investor's Business Daily
10:48AM  Merck's once-weekly diabetes drug found effective in study
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co. Inc formerly operated as a subsidiary of Merck KGaA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise39.2956,0642,202,755206,496May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Sale60.2056,0643,374,795150,432May 05 04:46 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,818025,359May 05 04:46 PM
Golestani ClarkEVP & Chief Info OfficerMay 02Option Exercise0.002,291010,259May 05 04:46 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 02Option Exercise0.008,6540116,334May 05 04:46 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 02Option Exercise0.004,709015,129May 05 04:46 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 02Option Exercise0.003,818034,534May 05 04:46 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 02Option Exercise0.0019,343019,343May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 02Option Exercise0.0011,7080156,503May 05 04:46 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 02Option Exercise0.003,818020,794May 05 04:46 PM
Deese Willie AExe V-P & Pres. MMDMay 02Option Exercise0.007,6360122,631May 05 04:46 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthMay 02Option Exercise0.005,090014,564May 05 04:46 PM
Holston Michael JEVP, LegalApr 29Option Exercise44.39135,6246,020,460135,624Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Option Exercise38.51156,9026,042,441301,697Apr 29 06:01 PM
Holston Michael JEVP, LegalApr 29Sale59.8495,6245,722,54240,000Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Sale59.82156,9029,386,646144,795Apr 29 06:01 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM